Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

Gut, Airway and Tumor Microbes Emerge as Promising Predictors of Immunotherapy Response in Lung Cancer

Only 20% to 40% of patients with non small cell lung cancer (NSCLC) respond to immune checkpoint inhibitors, leaving the majority without meaningful clinical benefit. Current biomarkers such as programmed death ligand 1 (PD L1) expression and tumor mutational burden have limited predictive accuracy.

September 9, 2026


September 9 2026

September 8 2026

September 7 2026

September 5 2026

September 4 2026

September 3 2026

September 2 2026

September 1 2026

August 31 2026

August 30 2026

August 29 2026

August 28 2026

August 27 2026

August 26 2026